Healthcare Global Enterprises posted a good set of second quarter earnings. The Year on Year (YoY) consolidated revenues were up 21.3 percent to Rs 211 crore versus Rs 174 crore.
The consolidated EBITDA wa up 22.3 percent to Rs 31 crore versus Rs 25 crore for the same period last fiscal. The consolidated margins were up marginally to 14.7 percent from 14.6 percent YoY.
BS Ajaikumar, Chairman & CEO, Healthcare Global Enterprises said in spite of starting new centers at a group level, we have maintained margins at 14.7 percent and the existing centers have shown margins of 18.7 percent. Going forward the existing centers will continue to do well and the new centers are also doing extremely well.
All the new centers on track to do EBITDA breakeven in the first year itself, said Ajaikumar.
For the cancer centers the YoY growth has been in region of 22 percent, and while the new infertility centers are ramping up, the growth there is below 20 percent. However, existing centers continue to do well.
The contribution of infertility centers is less than 10 percent in the overall group businesses.
As of now the total number of oncology centers are around 20, said Ajaikumar, adding that in the coming two centers the number will be around 24-25. They have 8 infertility centers of now, which will be ramped up further.
Healthcare Global Enterprises Ltd (HCG) is India’s largest provider of cancer care. Through its network of 18 comprehensive cancer centers spread across India, HCG has brought advanced cancer care to the doorstep of millions of people.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
